Amcenestrant - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?

Representative image of a motorway corridor and capital flows illustrating HICL Infrastructure PLC’s £311 million A63 Motorway stake sale in France, as the London-listed infrastructure investor exits the Atlandes asset at a 21% premium to book value.

HICL Infrastructure (LSE: HICL) to sell A63 Motorway stake for £311m at 21% premium to book value

Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?

Representative image illustrating PROTAC-mediated targeted protein degradation of the estrogen receptor in ER+ breast cancer, a novel approach used by vepdegestrant to overcome endocrine resistance.

Read More

5 minute read

Pharma Industry News

PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?

Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.

byPallavi Madhiraju

June 9, 2025

web analytics